Cipla is scheduled to release its Q2 earnings on October 29. Analysts expect the company to experience modest growth due to a lack of significant drug launches in the US market and a high comparative base.

According to predictions from a Moneycontrol poll of eight brokerages, net profit is expected to increase by approximately 5 percent, reaching Rs 1,215 crore, compared to Rs 1,155.82 crore in the same quarter last year. Revenue is also anticipated to grow by 5 percent, totaling Rs 6,996 crore, up from Rs 6,678.15 crore in the previous fiscal period. The operational performance is projected to remain stable, with the EBITDA margin expected to be around 26 percent, a slight improvement from 25.6 percent in the prior year.

The earnings forecasts show a tight range, with the most optimistic estimate predicting an 18 percent rise in net profit, while the most cautious outlook suggests a nearly 2 percent decline. Overall, most brokerages anticipate a rise in Cipla's net profit, with only B&K Securities forecasting a decrease.